MF Conclusion Was 5 Recommend Buy Or OutPerform And 4 Say Hold
QCOR..beating market expectations for revenue and earnings in each quarter for two years,
great product, good management,
pays a tidy dividend ($.80 per share and yielding over 3%),
strong fundamentals going forward, exceeding expectations,
sales of $865 million including $424 million in the previous year,
substantial cash flows from its operations,
aggressive marketing, increased scope of treatment coverage,
could be acquired by big pharma from previous MF article,
QCOR purchased BioVectra (the major supplier for Achtar) for $50 million cash to firm up its supply side and to prevent competition for Achtar from entering the market.
Aetna still covers Achtar on a case by case basis (info from Aetna and QCOR) even though they claimed there would be limited coverage....Every couple of weeks a research group would print the Aetna story as if it was new news.
The U.S. agency investigating promotional practices for marketing is a Philadelphia District Attorney somewhere in Philadelphia, PA...no recent news about anything.....
Cerium Pharmaceuticals is a garage connected to a house in (Maryland??)...Someone claimed that they sought orphan drug status for a synthetic form of Achtar....QCOR should have orphan drug protection until at least 2017.
Trading at a substantial discount due to negative news but is an extremely attractive investment
with significant upside potential
Was a $50 stock in 2012 before negative news started around August-September, 2012
That was the most ridiculous MF article yet... who writes this stuff? starts off negative then has a negative tone through out even says; the "most daming" news of all the bio-vectra acquition... lols... then in the final conclusion basically a "buy" at these levels... psychofrenic author.... but did MF just turn bullish? Curious.